COMMUNIQUÉS West-GlobeNewswire

Option Care Health Announces Financial Results for the Second Quarter Ended June 30, 2025
30/07/2025
BANNOCKBURN, Ill., July 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
30/07/2025
Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end [...]
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
30/07/2025
Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research MENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company [...]
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
30/07/2025
Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed [...]
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
30/07/2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar [...]
AB Science a reçu l’approbation règlementaire de pays européens pour initier la troisième étape de la phase I/II visant à combiner sa molécule AB8939 avec le venetoclax dans le traitement de la LMA
30/07/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE A RECU L’APPROBATION REGLEMENTAIRE DE PAYS EUROPEENS POUR INITIER LA TROISIEME ETAPE DE LA PHASE I/II VISANT A COMBINER SA MOLÉCULE AB8939 AVEC LE VENETOCLAX DANS LE TRAITEMENT DE LA [...]
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
30/07/2025
PRESS RELEASE AB SCIENCE RECEIVES REGULATORY APPROVAL FROM EUROPEAN COUNTRIES TO INITIATE THIRD STAGE OF PHASE I/II STUDY COMBINING ITS MOLECULE AB8939 WITH VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA THE [...]
Leading European Shipbuilder Selects Aino’s SaaS Platform
30/07/2025
Aino Health AB (publ) has signed an agreement with one of Europe’s leading shipbuilding companies for the implementation of the Aino SaaS platform. The agreement covers 2,000 employees and aims to strengthen the [...]
Clenbuterol for Sale: The Complete Guide to Buying Real Clen Pills Online Without Getting Scammed
30/07/2025
Clenbuterol for Sale: Where to Buy Real Clen Pills Online Without Risking Your Health or Wallet In recent years, Clenbuterol has surged in popularity among athletes and bodybuilders looking for an effective way to shed [...]
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
30/07/2025
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
30/07/2025
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to the same period in 2024, [...]
Communiqué de presse: Le SAR446523 de Sanofi, un anticorps monoclonal anti-GPRC5D, se voit accorder la désignation médicament orphelin pour le myélome multiple aux États-Unis
30/07/2025
Le SAR446523 de Sanofi, un anticorps monoclonal anti-GPRC5D, se voit accorder la désignation médicament orphelin pour le myélome multiple aux États-Unis Désignation accordée pour l’anticorps monoclonal GPRC5D à base d’ [...]
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
30/07/2025
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with [...]
Investor Confidence Shaken as Senegal Detains Oil Executive and Philanthropist Khadim Ba Amid Global Outcry
30/07/2025
UN Ambassador warns of economic fallout and reputational damage as key donor to Senegal remains jailed despite lack of evidence LOS ANGELES, July 29, 2025 (GLOBE NEWSWIRE) -- UN Peace Ambassador Dr. Michael K. Obeng, [...]
J-Star Holding Announces Pricing of $5.0 Million Initial Public Offering
30/07/2025
TAICHUNG CITY, Taiwan, July 29, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications [...]
Inventiva publie ses informations financières préliminaires du premier semestre 2025¹
29/07/2025
Trésorerie et équivalents de trésorerie de 122,1 millions d’euros et 24,6 millions d’euros de dépôts à court terme 2 au 30 juin 2025 Chiffre d’affaires de 4,5 millions d’euros au premier semestre 2025 Daix (France), New [...]
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
29/07/2025
Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits 2 as of June 30, 2025 Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City (New York, United States), July 29, [...]
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
29/07/2025
- Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with [...]
Larimar Therapeutics Announces Proposed Underwritten Public Offering
29/07/2025
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]

Pages